UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.609

Sortiert nach

Uveal melanoma: From diagnosis to treatment and the science in between

Cancer, 2016-08, Vol.122 (15), p.2299-2312

2016

Link zum Volltext

Verfügbarkeit prüfen

Vulvar and vaginal melanoma: A unique subclass of mucosal melanoma based on a comprehensive molecular analysis of 51 cases compared with 2253 cases of nongynecologic melanoma

Cancer, 2017-04, Vol.123 (8), p.1333-1344

2017

Link zum Volltext

Verfügbarkeit prüfen

Clinical outcomes in metastatic uveal melanoma treated with PD‐1 and PD‐L1 antibodies

Cancer, 2016-11, Vol.122 (21), p.3344-3353

2016

Link zum Volltext

Verfügbarkeit prüfen

NRAS mutation status is an independent prognostic factor in metastatic melanoma

Cancer, 2012-08, Vol.118 (16), p.4014-4023

2012

Link zum Volltext

Verfügbarkeit prüfen

High neutrophil‐to‐lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PD‐1 inhibitor monotherapy

Cancer, 2020-01, Vol.126 (1), p.76-85

2020

Link zum Volltext

Verfügbarkeit prüfen

The efficacy of anti‐PD‐1 agents in acral and mucosal melanoma

Cancer, 2016-11, Vol.122 (21), p.3354-3362

2016

Link zum Volltext

Verfügbarkeit prüfen

A phase 2 trial of complete resection for stage IV melanoma

Cancer, 2011-10, Vol.117 (20), p.4579-4581

Ollila, David W.

2011

Link zum Volltext

Verfügbarkeit prüfen

Immune and molecular correlates in melanoma treated with immune checkpoint blockade

Cancer, 2017-06, Vol.123 (S11), p.2143-2153

2017

Link zum Volltext

Verfügbarkeit prüfen

Tumor cell expression of programmed cell death‐1 ligand 1 is a prognostic factor for malignant melanoma

Cancer, 2010-04, Vol.116 (7), p.1757-1766

2010

Link zum Volltext

Verfügbarkeit prüfen

Active surveillance of patients who have sentinel node positive melanoma: An international, multi‐institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT‐2)

Cancer, 2021-07, Vol.127 (13), p.2251-2261

2021

Link zum Volltext

Verfügbarkeit prüfen

Use of immunotherapy and surgery for stage IV melanoma

Cancer, 2020-06, Vol.126 (11), p.2614-2624

2020

Link zum Volltext

Verfügbarkeit prüfen

The impact of targeted therapies and immunotherapy in melanoma brain metastases: A systematic review and meta‐analysis

Cancer, 2019-11, Vol.125 (21), p.3776-3789

2019

Link zum Volltext

Verfügbarkeit prüfen

Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma

Cancer, 2015-11, Vol.121 (22), p.4007-4015

2015

Link zum Volltext

Verfügbarkeit prüfen

Does skin cancer screening save lives? A detailed analysis of mortality time trends in Schleswig‐Holstein and Germany

Cancer, 2016-02, Vol.122 (3), p.432-437

2016

Link zum Volltext

Verfügbarkeit prüfen

Phase 2 study of RO4929097, a gamma‐secretase inhibitor, in metastatic melanoma: SWOG 0933

Cancer, 2015-02, Vol.121 (3), p.432-440

2015

Link zum Volltext

Verfügbarkeit prüfen

Melanoma: What do all the mutations mean?

Cancer, 2018-09, Vol.124 (17), p.3490-3499

2018

Link zum Volltext

Verfügbarkeit prüfen

Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery

Cancer, 2016-10, Vol.122 (19), p.3051-3058

2016

Link zum Volltext

Verfügbarkeit prüfen

Circulating tumor DNA‐based molecular residual disease detection for treatment monitoring in advanced melanoma patients

Cancer, 2023-06, Vol.129 (11), p.1723-1734

2023

Link zum Volltext

Verfügbarkeit prüfen

Mucosal melanoma of the nose and paranasal sinuses, a contemporary experience from the M. D. Anderson Cancer Center

Cancer, 2010-05, Vol.116 (9), p.2215-2223

2010

Link zum Volltext

Verfügbarkeit prüfen

Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors

Cancer, 2014-06, Vol.120 (11), p.1695-1701

2014

Link zum Volltext

Verfügbarkeit prüfen

Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma

Cancer, 2012-05, Vol.118 (9), p.2476-2485

2012

Link zum Volltext

Verfügbarkeit prüfen

Single-Institution Experience With Ipilimumab in Advanced Melanoma Patients in the Compassionate Use Setting: Lymphocyte Count After 2 Doses Correlates With Survival

Cancer, 2010-04, Vol.116 (7), p.1767-1775

2010

Link zum Volltext

Verfügbarkeit prüfen

An independent validation of a gene expression signature to differentiate malignant melanoma from benign melanocytic nevi

Cancer, 2017-02, Vol.123 (4), p.617-628

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 1.609

Suche als RSS-Feed

Aktive Filter

SpracheDeutsch

Zeitschrift / SerieCancer

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.609)
Mit Volltextzugriff
(1.609)

Publikationsform

Artikel
(1.609)

Sprache

Englisch
(1.609)
Japanisch
(161)

Erscheinungsjahr

n.n

Thema

Humans
(1.380)
Oncology
(1.277)
Life Sciences & Biomedicine
(1.238)
Science & Technology
(1.238)
Female
(961)
Male
(903)
Middle Aged
(797)
Adult
(712)
Biological And Medical Sciences
(645)
Medical Sciences
(642)
Aged
(626)
Melanoma - Pathology
(552)
Melanoma
(527)
Skin Neoplasms - Pathology
(397)
Dermatology
(381)
Tumors Of The Skin And Soft Tissue. Premalignant Lesions
(373)
Prognosis
(317)
Melanoma - Drug Therapy
(270)
Tumors
(259)
Adolescent
(242)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

5 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Cancer Cytopathology
(5)
Cancer Radiothérapie
(1)

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Uveal melanoma: From diagnosis to treatment and the science in between

Vulvar and vaginal melanoma: A unique subclass of mucosal melanoma based on a comprehensive molecular analysis of 51 cases compared with 2253 cases of nongynecologic melanoma

Clinical outcomes in metastatic uveal melanoma treated with PD‐1 and PD‐L1 antibodies

NRAS mutation status is an independent prognostic factor in metastatic melanoma

High neutrophil‐to‐lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PD‐1 inhibitor monotherapy

The efficacy of anti‐PD‐1 agents in acral and mucosal melanoma

A phase 2 trial of complete resection for stage IV melanoma

Immune and molecular correlates in melanoma treated with immune checkpoint blockade

Tumor cell expression of programmed cell death‐1 ligand 1 is a prognostic factor for malignant melanoma

Active surveillance of patients who have sentinel node positive melanoma: An international, multi‐institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT‐2)

A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG‐ACRIN Cancer Research Group (E2607)

Use of immunotherapy and surgery for stage IV melanoma

The impact of targeted therapies and immunotherapy in melanoma brain metastases: A systematic review and meta‐analysis

Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma

Does skin cancer screening save lives? A detailed analysis of mortality time trends in Schleswig‐Holstein and Germany

Quality‐of‐life assessment in French patients with metastatic melanoma in real life

Phase 2 study of RO4929097, a gamma‐secretase inhibitor, in metastatic melanoma: SWOG 0933

Melanoma: What do all the mutations mean?

Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery

Circulating tumor DNA‐based molecular residual disease detection for treatment monitoring in advanced melanoma patients

Mucosal melanoma of the nose and paranasal sinuses, a contemporary experience from the M. D. Anderson Cancer Center

Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors

Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma

Single-Institution Experience With Ipilimumab in Advanced Melanoma Patients in the Compassionate Use Setting: Lymphocyte Count After 2 Doses Correlates With Survival

An independent validation of a gene expression signature to differentiate malignant melanoma from benign melanocytic nevi

Aktive Filter

Suchergebnisse filtern